Vaccine Adjuvants Market is expected to reach $769.4 Million by 2021, at a CAGR of 10.5%.
Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021
(firmenpresse) - The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period. This market is mainly driven by factors such as rising prevalence of diseases such as allergy, cancer, and HIV/AIDS; growing demand for advanced treatment options, and development of improved vaccine immunization.
On the basis of applications, the market is segmented into research and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as ongoing research projects on new adjuvants, increasing initiatives by government bodies and companies, growing usage of many vaccine adjuvants commercially, and increasing incidences of zoonotic diseases.
On the basis of application categories, the market is segmented into human vaccine adjuvants and veterinary vaccine adjuvants. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is also expected to grow at the higher CAGR. The large share of this segment can primarily be attributed to factors such as increasing initiatives by companies.
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
Get More Details: https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.09.2018 - 21:17 Uhr
Sprache: Deutsch
News-ID 581330
Anzahl Zeichen: 2915
contact information:
Kategorie:
Healthcare & Medical
Typ of Press Release: Erfolgsprojekt
type of sending: Veröffentlichung
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vaccine Adjuvants Market is expected to reach $769.4 Million by 2021, at a CAGR of 10.5%."
steht unter der journalistisch-redaktionellen Verantwortung von
marketsandmarkets (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
